Cluster of differentiation 3 (CD3) T-cell receptor complex (CD3)

The CD3 T-cell receptor complex is a multi-subunit protein assembly essential for the activation of T lymphocytes. It consists of four distinct chains—gamma (γ), delta (δ), epsilon (ε), and zeta (ζ)—that non-covalently associate with the T-cell receptor (TCR) heterodimer to form a functional signaling unit (UniProt P07766, P04234) [1]. When the TCR recognizes a specific antigen presented by the major histocompatibility complex (MHC), the CD3 subunits transduce the activation signal into the cell through immunoreceptor tyrosine-based activation motifs (ITAMs) located in their cytoplasmic tails (StatPearls, T Cell Receptors) [2]. This signaling process is a critical step in the adaptive immune response, leading to T-cell proliferation, cytokine production, and effector function. In clinical practice, CD3 is a major therapeutic target; for instance, Teplizumab is used to delay the progression of Type 1 Diabetes by modulating T-cell responses (FDA, 2022) [3]. Additionally, CD3 is the primary anchor for bispecific T-cell engagers (BiTEs) and other bispecific antibodies, such as Blinatumomab, which redirect T-cell cytotoxicity toward malignant cells (PubMed, PMC5463604) [4]. However, therapeutic targeting of CD3 can trigger significant safety issues, most notably cytokine release syndrome (CRS) due to systemic T-cell activation.

Other names

CD3 antigenT3 complexT-cell surface glycoprotein CD3T-cell receptor-CD3 complex

The CD3 complex is targeted to either suppress or activate the immune system. Immunosuppressive agents like Muromonab-CD3 and Teplizumab work by binding to the CD3 epsilon chain, leading to TCR internalization, T-cell depletion, or the induction of anergy. Conversely, bispecific T-cell engagers (BiTEs) and bispecific antibodies (e.g., Blinatumomab, Teclistamab) bind CD3 to physically link T cells to tumor cells, triggering T-cell activation and directed lysis of the target cell (PubMed, PMC5463604; FDA Label) [4, 5].